Agendia B.V.

Agendia to Present Broad Array of Data at 2009 San Antonio Breast Cancer Symposium

    Huntington Beach, California and Amsterdam (ots/PRNewswire)
--        Agendia, a world leader in molecular cancer diagnostics,
announced today that it will be presenting six studies focusing on
MammaPrint(R) at the 2009 San Antonio Breast Cancer Symposium
(SABCS), one of the premiere conferences in breast cancer research
worldwide. The SABCS will take place December 9-13, at the Henry B.
Gonzalez Convention Center in San Antonio, Texas, USA.

    Agendia's studies to be presented at the SABCS further establish the broad predictive and prognostic power of MammaPrint, the only FDA-cleared breast cancer recurrence test available to patients and physicians. Conference attendees can meet the Agendia team at booth #556.

    Study results will be discussed at the following sessions:

    Date: Thursday, December 10, 2009

    Time: 5:30 pm - 7:30 pm

    Poster presentation (102)

    Combining Genomic Profiling (70 Gene-MammaPrint) with Nodal Status Allows to Classify Patients with Primary Breast Cancer and Positive Lymph Nodes (1-9) into Very Distinct Prognostic Subgroups That Could Help Tailor Treatment Strategies

    Saghatchian M, Mook S, Pruneri G, Viale G, Glas A, Eekhout I, Delaloge S, van 't Veer L. Institut Gustave Roussy, Villejuif, France; Netherlands Cancer Institute, Amsterdam, The Netherlands; European Institute of Oncology, Milan, Italy; Agendia BV, Amsterdam, The Netherlands.

    Date: Friday, December 11, 2009

    Time: 7 am - 9 am

    Poster presentation (2026)

    Basal-, Luminal-, and HER2- Molecular Subtype, and the MammaPrint 70-Gene Signature as Predictors of Response to Neoadjuvant Chemotherapy (NCT) with Docetaxel, Doxorubicin, Cyclophosphamide (TAC), or AC and Nab-Paclitaxel and Carboplatin +/- Trastuzumab in Patients (pts) with Stage II-III and Inflammatory Breast Cancer (BC)

    Somlo G, Lau S, Frankel P, Garberoglio C, Kruper L, Yen Y, Luu T, Hurria A, Chung CT, Mortimer J, Yim J, Paz IBe, Krijgsman O, Delahaye L, Stork-Sloots L, Bender R. City of Hope Comprehensive Cancer Center, Duarte, CA; Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA.

    Date: Saturday, December 12, 2009

    Time: 7 am - 9 am

    Poster presentation (4049)

    The 70-Gene Profile (MammaPrint) Is an Independent Predictor of Breast Cancer Specific Survival for Women 65 Years of Age or Older

    Bedard PL, Mook S, Knauer M, Durbecq V, Bernard-Marty C, Glas AM, Cardoso F, van 't Veer LJ. Jules Bordet Institute, Brussels, Belgium; Netherlands Cancer Institute, Amsterdam, The Netherlands; TRANSBIG Consortium, Brussels, Belgium; Agendia BV, Amsterdam, The Netherlands

    Date: Sunday, December 13, 2009

    Time: 7 am - 8:30am

    Poster presentation (6131)

    Molecular Subtype Profile Reveals Therapy Predictive Power

    de Snoo FA, Krijgsman O, Roepman P, Bender RA, Glas AM. Agendia BV, Amsterdam, The Netherlands; Agenda, Inc., Huntington Beach, CA..

    Date: Sunday, December 13, 2009

    Time: 7 am - 8:30am

    Poster presentation (6146)

    Biological Functions of Genes in the 70-Gene MammaPrint Tumor Expression Profile Reflect Molecular Mechanism of Tumor Metastasis

    Glas AM, Tian S, Roepman P, Krijgsman O, Van 't Veer LJ, de Snoo F. Agendia BV, Amsterdam, The Netherlands; The Netherlands Cancer Institute, Amsterdam, The Netherlands.

    About MammaPrint(R)

    MammaPrint is the first and only breast cancer recurrence test cleared by  the U.S. Food and Drug Administration (FDA). FDA clearance under the in vitro diagnostic multivariate index assay (IVDMIA) guidelines requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis risk - patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test results provide doctors with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.

    All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.

    About Agendia

    Agendia is at the forefront of the personalized medicine revolution,  striving to bring more effective, individualized treatments within reach of  patients. Building on a cutting-edge genomics platform for tumor gene  expression profiling, the company's tests help physicians more accurately  tailor cancer treatments. Agendia markets three products, with several new  genomic tests under development. In addition, Agendia collaborates with  pharmaceutical companies to develop highly effective personalized drugs in  the area of oncology. Agendia is based in Huntington Beach, California, and in Amsterdam, The Netherlands.

ots Originaltext: Agendia B.V.
Im Internet recherchierbar: http://www.presseportal.ch

Contact:
Media contacts: Hans Herklots, Head of Corporate Communications,
Agendia, +31-20-462-1557 Office, +31-620-083-509 Mobile,
hans.herklots@agendia.com. Valerie Delva, Account Executive, Ricochet
Public Relations, +1-212-679-3300 x131 Office, vdelva@ricochetpr.com



Weitere Meldungen: Agendia B.V.

Das könnte Sie auch interessieren: